Oscillating Positive Expiratory Pressure Therapy for Patients With Thoracic Neoplasms Undergoing … (NCT05267496) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Oscillating Positive Expiratory Pressure Therapy for Patients With Thoracic Neoplasms Undergoing Chest Surgery
Mexico72 participantsStarted 2019-08-13
Plain-language summary
This randomized clinical study aims to assess the use of an oscillating positive expiratory pressure device (AEROBIKA) in patients with thoracic neoplasms who undergo chest surgery.
The main questions it aims to answer are:
If the use of the AEROBIKA device reduces the incidence of atelectasis in oncological patients undergoing lung resection.
If the use of the AEROBIKA device reduces hospital readmission and days of hospital stay.
Participants who accept to participate will be sorted to receive a conventional rehab therapy (group A), otherwise a conventional rehab therapy plus AEROBIKA device (group B).
Researchers will compare patients from group A versus group B to see if patients develop atelectasis.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients with a confirmed diagnosis of lung cancer, mediastinal tumors or mesothelioma who are candidates for surgical resection through thoracotomy or sternotomy.
. Measurable disease
. Age from 18 to 75 years
. Peak Expiratory flow of 10 liters/min
. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
. Karnofsky score 70-100
. Patients willing and able to comply with all study procedures and follow-up visits.
. Patients who agree to participate and sign an informed consent form
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Reduction of lung atelectasis
Timeframe: Radiographs will be taken after 3 months of surgery
Trial details
NCT IDNCT05267496
SponsorInstituto Nacional de Cancerologia de Mexico